Abstract:Choroidal neovascularization (CNV) is the leading cause of vision loss in many blinding diseases, but current antiangiogenic therapies with invasively intravitreal injection suffer from poor patient compliance and a rate of devastating ocular complications. Here, we develop an alternative antiangiogenic agent based on hybrid cell-membrane-cloaked nanoparticles for noninvasively targeted treatment of CNV. The retinal endotheliocyte membrane coating provides as-fabricated nanoagents with homotypic targeting capability and binding ability to the vascular endothelial growth factor. The fusion of red blood cell membranes protects the hybrid membrane-coated nanoparticles from phagocytosis by macrophages. In a laser-induced wet age-related macular degeneration mouse model, a significantly enhanced accumulation is observed in CNV regions after intravenous delivery of the hybrid membrane-coated nanoparticles. Moreover, an excellent therapeutic efficacy is achieved in reducing the leakage and area of CNV. Overall, the biomimetic antiangiogenic nanoagents provide an effective approach for noninvasive treatment of CNV.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.1c00680?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.1c00680</a>.Confirmation of complete hybrid membrane coating onto PLGA nanoparticle cores (Figure S1); long-term stability of [RBC-REC]NPs (Figure S2); self-recognition capability of RECNPs and [RBC-REC]NPs in vitro (Figure S3); targeting affinity to angiogenic endothelial cells in vitro (Figure S4); macrophage uptake of nanoparticles in vitro (Figure S5); biodistribution of nanoparticles in vivo (Figure S6); representative fundus photographs in the day 7 (Figure S7); active-targeting capability of [RBC-REC]NPs in CNV (Figure S8); ability of [RBC-REC]NPs in suppressing endothelial cell migration in vitro (Figure S9); cytotoxic assessment to different ocular cells (Figure S10); biosafety assessment of as-fabricated nanoparticles (Figure S11) (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.1c00680/suppl_file/nn1c00680_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

ROS-responsive charge reversal mesoporous silica nanoparticles as promising drug delivery system for neovascular retinal diseases

Reactive Oxygen Species-Responsive Nanotherapy for the Prevention and Treatment of Cerebral Ischemia–reperfusion Injury

Recent Advances and Prospects for Lipid-Based Nanoparticles As Drug Carriers in the Treatment of Human Retinal Diseases

C176-loaded and Phosphatidylserine-Modified Nanoparticles Treat Retinal Neovascularization by Promoting M2 Macrophage Polarization

Clickable Corneal Neovascularization Therapy with ROS-Responsive Polydopamine Silica Nanoparticles Loaded with Fenofibrate

ROS-Responsive Nanoparticles with Antioxidative Effect for the treatment of Diabetic Retinopathy

Polydopamine nanoparticles attenuate retina ganglion cell degeneration and restore visual function after optic nerve injury

Targeted Noninvasive Treatment of Choroidal Neovascularization by Hybrid Cell-Membrane-Cloaked Biomimetic Nanoparticles

ROS responsive resveratrol delivery from LDLR peptide conjugated PLA-coated mesoporous silica nanoparticles across the blood-brain barrier

Mesoporous Silica Nanoparticles As a Delivery System for Improving Antiangiogenic Therapy

Reactive Oxygen Species─Responsive Lipid Nanoparticles for Effective RNAi and Corneal Neovascularization Therapy

Self-Assembly Hypoxic and ROS Dual Response Nano Prodrug as a New Therapeutic Approach for Glaucoma Treatments

Mesoporous Silica-Based Nanoparticles as Non-Viral Gene Delivery Platform for Treating Retinitis Pigmentosa

A Homing Peptide Modified Neutrophil Membrane Biomimetic Nanoparticles in Response to ROS/inflammatory Microenvironment for Precise Targeting Treatment of Ischemic Stroke

Antiangiogenic Nanomicelles for the Topical Delivery of Aflibercept to Treat Retinal Neovascular Disease

Targeted Long-term Noninvasive Treatment of Choroidal Neovascularization by Biodegradable Nanoparticles

Nanoparticle‐based sustained drug delivery for the treatment of ocular neovascular diseases

ROS-responsive Biomimetic Nanoparticles for Potential Application in Targeted Anti-Atherosclerosis

Sustaining Intravitreal Residence With L-Arginine Peptide-Conjugated Nanocarriers

Emerging Co-Assembled and Sustained Released Natural Medicinal Nanoparticles for Multitarget Therapy of Choroidal Neovascularization

Temperature-sensitive Copolymer-Coated Fluorescent Mesoporous Silica Nanoparticles As a Reactive Oxygen Species Activated Drug Delivery System.